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ABSTRACT
Objective  To evaluate golimumab’s effect on MRI-
detected spinal inﬂ  ammation in ankylosing spondylitis 
(AS).
Methods  Patients were randomly assigned to 
subcutaneous injections of placebo (n=78), golimumab 
50 mg (n=138), or golimumab 100 mg (n=140) every 
4 weeks. An MRI substudy comprising 98 patients 
(placebo n=23, 50 mg n=37, 100 mg n=38) at eligible 
MRI substudy sites had serial spine MRI scans (sagittal 
plane, 1.5T scanners, T1 and short tau inversion recovery 
sequences) at baseline and weeks 14 and 104. Two 
blinded (treatment, image order) readers independently 
evaluated MRI spinal inﬂ  ammation using AS spine 
MRI-activity (ASspiMRI-a) scores; reader scores were 
averaged. Changes from baseline to weeks 14 and 104 
were compared among treatment groups using analysis 
of variance on van der Waerden normal scores both with 
(post-hoc) and without (prespeciﬁ  ed) adjustment for 
baseline ASspiMRI-a scores.
Results  Median baseline ASspiMRI-a scores were lower 
in the 100 mg (3.5) than placebo (6.8) and 50 mg (7.8) 
groups. Median decreases in activity scores from baseline 
to week 14 were −0.5 for placebo, −3.5 for 50 mg 
(p=0.047 vs placebo), and −1.5 for 100 mg (p=0.14 vs 
placebo). After adjusting for baseline ASspiMRI-a score 
imbalance, signiﬁ  cant improvements were observed with 
both 50 mg (p=0.011) and 100 mg (p=0.002) versus 
placebo. ASspiMRI-a scores improvement achieved with 
golimumab was maintained at week 104. Improvement 
in ASspiMRI-a scores correlated with improvement in the 
recently developed AS disease activity score (ASDAS) 
and C-reactive protein (CRP) levels but not with other key 
AS clinical outcomes.
Conclusion  Golimumab signiﬁ  cantly reduced MRI-
detected spinal inﬂ  ammation of AS; improvements were 
sustained to week 104 and correlated with improvement 
in ASDAS and CRP.
Traditionally accepted disease assessments in anky-
losing spondylitis (AS) primarily comprise patient-
reported subjective measures, including pain, 
morning stiffness and fatigue. Objective measures 
of inﬂ  ammatory activity, such as C-reactive protein 
(CRP) or erythrocyte sedimentation rate, may not 
be elevated in active AS.1
Recent randomised, placebo-controlled studies 
have shown that MRI can objectively assess the 
effect of AS treatment interventions. In the larg-
est imaging study yet (n=279), inﬂ  iximab nearly 
eliminated MRI-detected spinal inﬂ  ammation 
after 24 weeks of therapy.2 Adalimumab has also 
effected sustained improvement in MRI-detected 
inﬂ  ammation in the spine and sacroiliac joints of 
AS patients.3 Smaller controlled4–6 and open-label7 
studies have also included MRI, some with data 
through 2 years of therapy.
In the GO-RAISE trial, patients with active AS 
showed signiﬁ  cant and sustained improvement in 
signs and symptoms with golimumab treatment.8 9 
Here we report ﬁ  ndings derived from a GO-RAISE 
MRI substudy.
METHODS
Details of the GO-RAISE study have been report-
ed.8 Adult patients with AS for 3 months or longer, 
Bath AS disease activity index (BASDAI) score of 4 
or greater (0–10-point scale), spinal pain assessment 
score of 4 or greater on a 0–10 cm visual analogue 
scale (VAS), and inadequate response to current/
previous non-steroidal anti-inﬂ  ammatory drugs or 
disease-modifying drugs were randomly assigned 
(1:1.8:1.8) to placebo, golimumab 50 mg, or goli-
mumab 100 mg injections every 4 weeks. Patients 
could continue stable methotrexate, sulfasalazine, 
hydroxychloroquine, corticosteroids and non-ste-
roidal anti-inﬂ  ammatory drug treatment.
At week 16, patients achieving less than a 20% 
improvement from baseline in the total back pain 
and morning stiffness scores entered double-blind 
early escape: patients randomly assigned to placebo 
received golimumab 50 mg, patients randomly 
assigned to golimumab 50 mg received 100 mg, 
and patients randomly assigned to golimumab 100 
mg did not change therapy. At week 24, patients 
still receiving placebo crossed over to golimumab 
50 mg.
The protocol was reviewed and approved by 
each site’s institutional review board or indepen-
dent ethics committee. All patients provided writ-
ten informed consent. The MRI substudy was 
conducted at 10 (of 57) sites with the capability 
and willingness to participate. All patients enrolled 
at participating substudy sites were included in the 
substudy.
Serial spine MRI scans of the cervical, thoracic 
and lumbar spine in the sagittal plane were acquired 
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ASAS20).11 Spearman correlation coefﬁ  cients were determined 
to assess relationships between ASspiMRI-a scores and other 
clinical measures, including BASDAI,12 AS disease activity score 
(ASDAS),13 physical function assessed by the Bath AS func-
tional index (BASFI),14 total back pain (10-cm VAS) and morn-
ing stiffness (10-cm VAS), and also for the relationship between 
ASspiMRI-a scores and serum CRP, an independent, objective 
measure of inﬂ  ammation.
Treatment group differences in the changes from baseline 
to week 14 were determined using two-sided analysis of vari-
ance (ANOVA) on the van der Waerden normal scores (α=0.05). 
Because of a disparity among treatment groups in baseline 
ASspiMRI-a scores, a post-hoc ANOVA adjusted for the baseline 
ASspiMRI-a score. No statistical comparisons were conducted 
at week 104 because all patients received golimumab from week 
24 onward.
To assess the correlation and reliability of the ASspiMRI-a 
scores at weeks 0, 14 and 104, 10% of images were re-read by 
each reader for the determination of inter-reader reliability coef-
ﬁ  cients, reﬂ  ecting the correlation between scores obtained for 
the same image by the two different readers at approximately 
the same time, and read-re-read reliability coefﬁ  cients, reﬂ  ecting 
the correlation between scores obtained for the same image by 
the same reader at two different times.15 The smallest detect-
able change in ASspiMRI-a scores at weeks 14 and 104 was 
determined.
RESULTS
Baseline demographics and disease characteristics
Baseline characteristics of the 98 MRI substudy participants 
are shown in table 2, along with baseline characteristics of 
the total study population. In the overall study population, 
patients in the placebo group were older, had longer disease 
duration, were more likely to demonstrate human leucocyte 
antigen B27 positivity, and were more likely to have a his-
tory of uveitis versus the golimumab groups.8 The median 
baseline CRP concentration was also higher in the placebo 
than golimumab groups. These differences were also evident 
and somewhat more pronounced in the substudy popula-
tion. Despite these differences, the substudy population was 
generally balanced for most characteristics of moderately to 
severely active AS at baseline and representative of the total 
study population.
MRI activity scores
Eighty-six (87.8%) of the 98 MRI substudy patients had a base-
line MRI obtained within the visit window and also had one 
or more postbaseline MRI image. At weeks 14 and 104, 7.0% 
(6/86) and 23.3% (20/86) of these patients, respectively, had 
ASspiMRI-a scores imputed due to missing data (see Methods 
section). When spinal segment (cervical, lumbar, thoracic) image 
quality was assessed, 55.4% (412/744) of the segments had one 
but not both readers designate the quality as ‘readable but not 
optimal’. Such images still yielded scoreable VU images unless 
a VU was considered unevaluable for activity scoring. When 
assessing image quality in individual VU, in 1.3% (77/5711) of 
with the patient in the supine position using 1.5 Tesla scanners 
and phase array spine or quadrature coils. Imaging sequences 
were T1 sagittal, turbo spin echo or fast spin echo without fat 
suppression, and short tau inversion recovery (STIR) sagittal 
(table 1).
Images were acquired at baseline (within 4 weeks of initial 
study agent administration) and within 1 week of the scheduled 
week 14 and week 104 visits. Seven of 98 (7.1%) MRI substudy 
patients had baseline MRI images obtained outside of the visit 
window that were excluded from analyses.
Two qualiﬁ  ed, experienced independent readers, blinded to 
treatment information, patient identity and chronology of the 
images, scored each sequence. All images were scored by each 
reader; reader scores for each image were averaged. A randomly 
selected 10% sample of MRI substudy patients had images re-
scored by each reader 3 weeks or more after the initial scoring 
by that reader.
All 23 vertebral units (VU; C2–S1) were to be evaluated and 
scored for activity, ie, hyperintense bone marrow lesions (‘bone 
marrow oedema’) by STIR, and for erosions using the AS spine 
MRI-activity (ASspiMRI-a) score.5 10 A VU was deﬁ  ned as the 
area between two virtual horizontal lines through the middle 
of two adjacent vertebrae. Readers ﬁ  rst assessed technical ade-
quacy, or image quality, of the overall spinal segment (cervi-
cal, thoracic, lumbar) as optimal, readable but not optimal, or 
not readable and then scored each evaluable VU as follows: 0 
(no bone marrow oedema/erosions), 1 (minor bone marrow 
oedema involving ≤25% of the VU, no erosions), 2 (moderate 
bone marrow oedema involving >25% but ≤50% of the VU, no 
erosions), 3 (major bone marrow oedema involving >50% of the 
VU, no erosions), 4 (minor erosion involving ≤25% of the VU 
with minor bone marrow oedema), 5 (moderate erosion involv-
ing >25% but ≤50% of the VU with bone marrow oedema), 
or 6 (major erosion involving >50% of the VU with bone mar-
row oedema). An unevaluable VU was designated ‘U’ (unable 
to score). The total ASspiMRI-a score range is 0–138. If one 
reader’s score was missing, the other reader’s score was used. If 
both readers’ scores were missing, patient data were considered 
missing. Only patients with baseline and one or more postbase-
line score were included in the analysis. If a week 14 or week 
104 score was missing, the score was imputed according to pre-
speciﬁ  ed methodology wherein the 75th percentile score for all 
patients at that time point was employed.
For the week 104 analysis, patients who entered early escape 
were included with their originally randomised group without 
the early escape imputation rule applied. For calculation of per-
centage change from baseline, if the baseline score was 0 and 
the postbaseline score was not 0, then the baseline score was 
set to 0.1. If both baseline and postbaseline scores were 0, then 
the percentage change from baseline was considered to be 0. 
Probability plots were constructed using observed data.
After adjusting for the baseline ASspiMRI-a score and treat-
ment group, multivariate regression analysis was employed to 
assess the relationship between ASspiMRI-a scores and clinical 
response (ie, proportion of patients achieving ≥20% improve-
ment in Assessment of AS International Working Group Criteria; 
Table 1  MRI protocol for sagittal cervical, thoracic and lumbar spine
Sequence TR (ms) TE (ms) TI (ms) Slice thickness (mm) Gap (%) FOV (cm) Matrix
T1 TSE or FSE   500 12 n/a Cervical/thoracic: 3; Lumbar: 4 0 20×40 128×512
STIR 4000 60 150 4 0 25×40 128×256
FOV, ﬁ  eld of view; FSE, fast spin echo; STIR, short tau inversion recovery; TE, echo time; TI, inversion time; TR, repetition time; TSE, 
turbo spin echo.
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ASspiMRI-a scores in the golimumab 50 mg and 100 mg groups 
were signiﬁ  cantly greater versus placebo (p=0.011 and p=0.002, 
respectively; table 3). The median percentage improvements in 
the ASspiMRI-a score from baseline to week 14 were signiﬁ  -
cantly greater in the golimumab 50 mg and 100 mg groups ver-
sus placebo (p=0.032 and p=0.025, respectively; table 3).
As illustrated in a probability plot (ﬁ  gure 1A), greater improve-
ment/less worsening in spinal inﬂ  ammation was observed at 
week 14 in golimumab-treated patients. Figures 1B, C illustrate 
the relationship between changes from baseline to week 14 and 
the corresponding baseline ASspiMRI-a score for each patient. 
In the combined golimumab group plot (ﬁ  gure 1C), points for 
baseline score and change scores generally mirror each other 
bisected by a virtual line that is close to 0, indicating nearly 
complete resolution of MRI-detected spinal inﬂ  ammation. 
Conversely, changes in the placebo group were independent 
of baseline activity, with the exception of two patients with 
VU one but not both readers considered it unevaluable for activ-
ity scoring.
The weighted κ coefﬁ  cient of the inter-reader agreement for 
ASspiMRI-a scoring was 0.44. The inter-reader reliability coef-
ﬁ  cients and read-re-read reliability coefﬁ  cients for ASspiMRI-a 
scores were 0.54 and 0.78, respectively, at week 0; 0.42 and 0.74, 
respectively, at week 14; and 0.57 and 0.86, respectively, at week 
104. The smallest detectable changes in ASspiMRI-a scores were 
6.64 and 2.57 at weeks 14 and 104, respectively.
Baseline ASspiMRI-a scores were lower in the golimumab 100 
mg group versus the placebo and golimumab 50 mg groups (table 
3). As per the planned analysis, the improvement in ASspiMRI-a 
score at week 14 was signiﬁ  cantly greater in the golimumab 
50 mg than the placebo groups (p=0.047), while the difference 
between golimumab 100 mg and placebo was not statistically 
signiﬁ  cant (p=0.14). In the post-hoc ANOVA that adjusted for 
disparities in baseline ASspiMRI-a scores, improvements in 
Table 2  Baseline demographics and disease characteristics for patients in the MRI substudy and the study population overall
Golimumab
Characteristic Placebo 50 mg 100 mg Combined
MRI substudy population
No of patients    23 37 38 75
Men 18 (78.3%) 26 (70.3%) 29 (76.3%) 55 (73.3%)
Age (years) 46.0 (40.0, 55.0) 38.0 (30.0, 45.0) 37.0 (30.0, 43.0) 37.0 (30.0, 44.0)
Years since inﬂ  ammatory back pain ﬁ  rst occurred 20.0 (13.0, 30.0) 10.0 (5.0, 14.0) 11.0 (5.0, 18.0) 10.0 (5.0, 18.0)
Years since diagnosis of AS 16.9 (5.3, 23.7) 4.5 (0.6, 11.5) 4.8 (0.7, 15.8) 4.5 (0.7, 13.5)
HLA-B27 positive 20 (87.0%) 29 (78.4%) 30 (78.9%) 59 (78.7%)
CRP (mg/dl) 1.6 (0.3, 2.7) 1.4 (0.6, 2.9) 0.6 (0.3, 1.3) 0.9 (0.3, 2.2)
ASDAS 4.3 (3.6, 4.5) 4.1 (3.3, 4.4) 3.9 (3.3, 4.2) 3.9 (3.3, 4.2)
BASDAI (0–10) 7.0 (6.0, 7.7) 6.2 (5.6, 7.8) 7.1 (6.2, 8.3) 6.7 (5.8, 8.0)
BASFI (0–10) 5.5 (4.1, 6.9) 5.4 (3.2, 6.8) 6.2 (4.8, 7.2) 5.8 (3.7, 7.1)
BASMI (0–10) 4.0 (3.0, 7.0) 3.0 (2.0, 4.0) 3.0 (2.0, 5.0) 3.0 (2.0, 5.0)
Total back pain (0–10) 8.0 (6.9, 8.8) 7.4 (5.5, 8.2) 8.0 (7.1, 8.7) 7.7 (6.4, 8.6)
Inﬂ  ammation (0–10) 7.1 (5.6, 8.6) 6.4 (5.7, 8.1) 7.6 (6.5, 9.2) 7.4 (5.7, 8.7)
Morning stiffness (min) 79.2 (54.0, 110.4) 75.6 (60.0, 96.0) 90.0 (60.0, 115.2) 90.0 (60.0, 105.6)
History of extra-axial involvement
  Uveitis 8 (34.8%) 6 (16.2%) 8 (21.1%) 14 (18.7%)
  Psoriasis 3 (13.0%) 2 (5.4%) 9 (23.7%) 11 (14.7%)
  Inﬂ  ammatory bowel disease 2 (8.7%) 6 (16.2%) 2 (5.3%) 8 (10.7%)
  Dactylitis 1 (4.3%) 0 (0.0%) 3 (7.9%) 3 (4.0%)
  Enthesitis 7 (30.4%) 9 (24.3%) 20 (52.6%) 29 (38.7%)
  Peripheral arthritis 5 (21.7%) 9 (24.3%) 11 (28.9%) 20 (26.7%)
Total study population
No of patients 78 138 140 278
Men 55 (70.5%) 102 (73.9%) 98 (70.0%) 200 (71.9%)
Age (years) 41.0 (31.0, 50.0) 38.0 (30.0, 47.0) 38.0 (29.0, 46.0) 38.0 (29.0, 46.0)
Years since inﬂ  ammatory back pain ﬁ  rst occurred 16.0 (6.0, 24.0) 11.0 (6.0, 19.0) 11.0 (5.0, 18.5) 11.0 (6.0, 19.0)
Years since diagnosis of AS 7.3 (2.8, 18.6) 5.2 (1.6, 11.6) 5.2 (1.5, 13.3) 5.2 (1.5, 12.3)
HLA-B27 positive 66 (84.6%) 112 (81.8%) 118 (84.3%) 230 (83.0%)
CRP (mg/dl) 1.15 (0.30, 2.40) 1.10 (0.50, 2.50) 0.90 (0.40, 2.50) 1.00 (0.40, 2.50)
BASDAI (0–10) 6.6 (5.7, 7.7) 6.6 (5.6, 7.6) 7.0 (6.0, 7.9) 6.8 (5.7, 7.7)
BASFI (0–10) 4.9 (3.5, 6.8) 5.0 (3.2, 6.7) 5.4 (3.4, 7.3) 5.2 (3.2, 6.9)
BASMI (0–10) 4.0 (2.0, 5.0) 3.0 (2.0, 4.0) 3.0 (2.0, 5.0) 3.0 (2.0, 5.0)
Total back pain (0–10) 7.6 (6.6, 8.8) 7.5 (5.7, 8.2) 7.9 (6.5, 8.8) 7.6 (6.1, 8.5)
Inﬂ  ammation (0–10) 7.1 (5.5, 8.3) 7.1 (5.4, 8.1) 7.6 (6.1, 9.0) 7.3 (5.7, 8.5)
Morning stiffness (min) 77.4 (45.6, 104.4) 77.4 (52.8, 99.6) 90.0 (60.0, 117.6) 90.0 (60.0, 112.8)
History of extra-axial involvement
  Uveitis 25 (32.1%) 28 (20.3%) 30 (21.4%) 58 (20.9%)
  Psoriasis 8 (10.3%) 7 (5.1%) 16 (11.4%) 23 (8.3%)
  Inﬂ  ammatory bowel disease 8 (10.3%) 11 (8.0%) 7 (5.0%) 18 (6.5%)
  Dactylitis 1 (1.3%) 9 (6.5%) 13 (9.3%) 22 (7.9%)
  Enthesitis 24 (30.8%) 50 (36.2%) 57 (40.7%) 107 (38.5%)
 Peripheral  arthritis 28 (35.9%) 49 (35.5%) 44 (31.4%) 93 (33.5%)
Values are n (%) or median (IQR).
AS, ankylosing spondylitis; ASDAS, ankylosing spondylitis disease activity score; BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis 
functional index; BASMI, Bath ankylosing spondylitis metrology index; CRP, C-reactive protein; HLA, human leucocyte antigen.
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percentages of patients with no inﬂ  ammation were comparable 
between the patient groups (61.9% and 66.7%, respectively; 
p=0.76).
By concordance of both readers, 14 (21.5%) of the 65 patients 
with available MRI data had baseline inﬂ  ammation on the MRI 
that persisted at week 104, although not necessarily in the same 
areas. When compared with the entire MRI substudy popula-
tion, the baseline characteristics in these patients were not dif-
ferent and no predictive factors were evident.
Relationships between MRI activity scores and clinical 
measures
Achievement of ASAS20 response was not signiﬁ  cantly associ-
ated with change from baseline in ASspiMRI-a score (multiple 
regression coefﬁ   cient (R)=0.62, p=0.17; data not shown). In 
the combined golimumab group, median (IQR) changes from 
high baseline ASspiMRI-a scores (>20 points), each of whom 
showed nearly complete reduction in inﬂ  ammatory activity at 
week 14.
In the golimumab groups, improvements (absolute/percent-
age change) in week 14 ASspiMRI-a scores were maintained to 
week 104 (table 3). Because all patients in the placebo group 
either entered early escape (week 16) or crossed over to goli-
mumab 50 mg (week 24), median percentage improvements 
from baseline to week 104 in the ASspiMRI-a score were simi-
lar to those observed in the golimumab groups. Representative 
images showing MRI-detected improvement in a golimumab-
treated patient (50 mg→100 mg) are provided in ﬁ  gure 2.
Among patients with a baseline ASspiMRI-a score greater than 
1, 54.2% of patients in the combined golimumab group showed 
no activity at week 14 compared with 20.0% of patients in the 
placebo group (p=0.0205; table 3). By week 104, approximately 
1.5 years after placebo patients crossed over to golimumab, the 
Table 3  Baseline and changes from baseline to weeks 14 and 104 in ASspiMRI-a score
Golimumab
MRI activity − ASspiMRI-a score Placebo* (n=23) 50 mg* (n=37) 100 mg (n=38) Combined (n=75)
Patients with baseline score and ≥1 post-baseline score to week 14    19   32   35   67
  Baseline ASspiMRI-a score=0 (no inﬂ  ammation)       2 (10.5%)     1 (3.1%)     8 (22.9%)     9 (13.4%)
  Baseline ASspiMRI-a score >0     17 (89.5%)   31 (96.9%)   27 (77.1%)   58 (86.6%)
Patients with baseline score and ≥1 postbaseline score to week 104     10   32   35   67
  Baseline  ASspiMRI-a  score=0  (no  inﬂ   ammation)    1  (10.0%)   1  (3.1%)   8  (22.9%)   9  (13.4%)
  Baseline ASspiMRI-a score >0       9 (90.0%)   31 (96.9%)   27 (77.1%)   58 (86.6%)
Baseline
  Mean  (SD)   9.6  (9.5)   9.3  (7.5)   5.0  (5.6)   7.1  (6.9)
  Median (IQR)      6.8 (1.4, 17.0)     7.8 (3.5, 15.5)     3.5 (1.5, 6.0)     5.5 (2.0, 10.5)
Change from baseline to week 14
  Mean (SD) −2.5 (8.9)   −5.9 (7.1) −3.2 (4.6) −4.5 (6.1)
  Median (IQR) −0.5 (−4.5, 2.5)   −3.5 (10.8, –0.3) −1.5 (−4.0, 0.0) −2.5 (−7.5, 0.0)
  ANOVA  p  value†   0.047      0.14   0.041
    Adjusted  ANOVA  p  value‡   0.011      0.002   0.003
Percentage improvement from baseline to week 14
  Mean (SD) −11.5 (132.3)   23.4 (210.1)   48.5 (43.4)   37.2 (143.9)
  Median (IQR) 1.8 (−26.3, 73.3)   84.7 (32.5, 100.0)   56.8 (0.0, 93.1)   72.1 (0.0, 100.0)
  ANOVA  p  value†   0.032   0.025   0.013
Change from baseline to week 104§
  Mean (SD) −10.4 (10.5)  −7.1 (7.3)  −3.6 (5.7)  −5.3 (6.7)
  Median (IQR) −7.3 (−19.0, –1.5)  −5.3 (−12.8, –0.8)   −1.5 (−6.0, 0.0)  −4.0 (−9.5, 0.0)
Percentage improvement from baseline to week 104§
  Mean (SD) −67.4 (509.2)   70.2 (52.4)   14.9 (200.5)   43.1 (146.4)
  Median (IQR) 79.0 (20.0, 100.0)   98.4 (69.6, 100.0)   77.8 (0.0, 100.0)   87.5 (33.3, 100.0)
Patients with inﬂ  ammation¶ at baseline and with week 14 data 15   23   25   48
  No (%) of patients with minimal inﬂ  ammation** at week 14       3 (20.0%)   13 (56.5%)   13 (52.0%)   26 (54.2%)
  p value vs placebo       0.0205
Patients with inﬂ  ammation¶ at baseline and with week 104 data 12   22   20   42
  No (%) of patients with minimal inﬂ  ammation** at week 104       8 (66.7%)   13 (59.1%)   13 (65.0%)   26 (61.9%)
  p value vs placebo   0.76
Patients with no inﬂ  ammation†† at baseline and with week 14 data 2     1     8     9
  Patients with any inﬂ  ammation‡‡ at week 14       0 (0.0%)     0 (0.0%)     0 (0.0%)     0 (0.0%)
Patients with no inﬂ  ammation†† at baseline and with week 104 data 2     1     5     6
  Patients with any inﬂ  ammation‡‡ at week 104       1 (50.0%)     0 (0.0%)     1 (20.0%)     1 (16.7%)
  p value vs placebo         0.35
*At week 16, patients in the placebo and 50 mg groups with less than 20% improvement from baseline in both the total back pain and morning stiffness scores entered early escape. 
Patients in the placebo group received golimumab 50 mg and patients in the golimumab 50 mg group received golimumab 100 mg. Patients who were originally assigned to the 
golimumab 100 mg group were not eligible for dose adjustment.
†ANOVA on the van der Waerden normal scores comparing the active treatment groups versus placebo.
‡ANOVA on the van der Waerden normal scores after adjusting for baseline ASspiMRI-a score because of the imbalance among the groups at baseline.
§All patients were receiving golimumab from week 24 to week 104. Patients who entered early escape were included in their originally assigned treatment group without data 
imputation.
¶ASspiMRI-a score>1.
**ASspiMRI-a score≤1.
††ASspiMRI-a score=0.
‡‡ASspiMRI-a score>0.
ANOVA, analysis of variance; ASspiMRI-a, ankylosing spondylitis spine magnetic resonance imaging activity.
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Figure 1  Panel A: Cumulative probability of changes in ASspiMRI-a scores from baseline to week 14 for each treatment group.  Each data point 
represents the change from baseline for an individual patient.  Panels B and C:  Double probability plots for the placebo and combined golimumab 
groups, respectively, showing the baseline ASspiMRI-a score plotted on top of the corresponding change from baseline to week 14 for each individual 
patient.
Figure 2  Magnetic resonance images of the cervical (C) and thoracic (T) spine at baseline (Panel A), week 14 (Panel B) and week 104 (Panel C) of 
a patient who received golimumab 50 mg followed by early escape at week 16 to golimumab 100 mg. These sagittal Short Tau Inversion Recovery 
(STIR) images show active lesions at multiple vertebral units, particularly at C7/T1 and T6/T7 at baseline (Panel A). The activity in the spine was 
markedly decreased at week 14 (Panel B) and resolved at nearly all levels at week 104 (Panel C).  Note: Series of consecutive images were evaluated; 
the images displayed here are representative but not exhaustive.
baseline to week 14 in the ASspiMRI-a score were 0.0 (−11.5, 
0.5) and −3.5 (−7.0, −0.5) in week 14 ASAS20 non-responders 
and responders, respectively (p=0.11; data not shown).
Conversely, there was a signiﬁ   cant positive correlation 
between changes at week 14 in ASspiMRI-a and ASDAS in the 
combined golimumab group (Spearman correlation coefﬁ  cient 
(r)=0.35, p=0.004) but not in the placebo group (r=0.39, p=0.09). 
Also, baseline ASDAS signiﬁ  cantly correlated with the change in 
ASspiMRI-a at both week 14 (r=−0.30, p=0.015) and week 104 
(r=−0.33, p=0.007) in the combined golimumab group.
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in golimumab-treated patients in this study.8 In the planned 
analysis, the improvement was statistically signiﬁ  cant only in 
the golimumab 50 mg group. However, when the analysis was 
repeated to adjust for disparities in baseline ASspiMRI-a scores 
(golimumab 100 mg group had substantially lower scores), the 
subcutaneous administration of both golimumab 50 mg and 100 
mg yielded statistically signiﬁ  cantly greater improvements in 
ASspiMRI-a scores versus placebo. Results of follow-up spinal 
MRI performed at week 104 indicated that these reductions in 
inﬂ  ammation were maintained through 2 years of treatment.
Although the magnitude of change from baseline in MRI-
detected inﬂ  ammation appeared to be numerically greater in the 
50 mg than the 100 mg group, the median improvement was 
similar in both groups when expressed as a percentage change 
from baseline. A clearly greater percentage reduction in spine 
inﬂ  ammation occurred by week 14 with golimumab than with 
placebo.
This substudy was limited by the relatively small number of 
patients in each treatment group, which ampliﬁ  ed disparities 
between the treatment groups in disease duration and led to 
inconsistencies in other important clinical parameters, including 
baseline ASspiMRI-a scores. Imputation of missing scores for 
approximately 7% and 23% of patients at weeks 14 and 104, 
respectively, had the potential to result in the generation of data 
outliers, which in turn impact mean values in groups of limited 
sample size. Furthermore, the large number of tests performed 
for these analyses could have resulted in spuriously signiﬁ  cant 
correlations. An additional study limitation is the only mod-
est level of agreement between the two readers. It is possible 
We failed to ﬁ  nd consistent correlations between ASspiMRI-a 
scores and other key clinical measures, including BASDAI, BASFI, 
total back pain and morning stiffness, among patients in the com-
bined golimumab group (table 4) or within the placebo group, 
with the exception of a Spearman correlation coefﬁ  cient (r) of 
−0.55 between baseline BASDAI scores and change from base-
line to week 104 in ASspiMRI-a score (p=0.014), which is after 
patients in the placebo group had crossed over to golimumab.
In contrast, strong and highly signiﬁ   cant correlations were 
observed in the combined golimumab group between baseline 
CRP levels and baseline ASspiMRI-a scores and between base-
line CRP levels and changes from baseline to weeks 14 and 104 
in ASspiMRI-a scores (table 4), such that higher baseline CRP lev-
els were associated with higher baseline ASspiMRI-a scores and 
with greater improvement in ASspiMRI-a scores from baseline 
to weeks 14 and 104. Also, changes from baseline to weeks 14 
and 104 in CRP levels signiﬁ  cantly correlated with changes from 
baseline to weeks 14 and 104 in the ASspiMRI-a score. In the pla-
cebo group, no correlations between CRP levels and ASspiMRI-a 
scores were observed (data not shown), except for a Spearman 
correlation coefﬁ  cient of 0.70 between the changes from baseline 
to week 14 in CRP levels and ASspiMRI-a scores (p<0.001).
DISCUSSION
The ﬁ  ndings derived from an MRI substudy of the GO-RAISE 
trial, which evaluated golimumab in the treatment of active AS,8 
indicate that golimumab signiﬁ   cantly reduced MRI-detected 
spinal inﬂ   ammation in patients with AS. These improve-
ments were consistent with the clinical beneﬁ  ts  observed 
Table 4  Spearman correlation coefﬁ  cients showing the correlations between measures of disease activity 
(BASDAI score) and MRI activity score and between inﬂ  ammation (CRP level) and MRI activity score for 
patients in the combined golimumab group
ASspiMRI-a score
  Baseline
Change from baseline 
to week 14
Change from baseline 
to week 104
CRP
 Baseline 0.38† −0.44‡ −0.40‡
  Change from baseline to week 14 0.45‡ 0.39†
  Change from baseline to week 104 0.38†
ASDAS
 Baseline 0.23 −0.30* −0.33†
  Change from baseline to week 14 0.35† 0.19
  Change from baseline to week 104 0.22
BASDAI
 Baseline 0.06 −0.06 −0.16
  Change from baseline to week 14 0.26* 0.16
  Change from baseline to week 104 0.11
BASFI
 Baseline 0.08 0.01 −0.21
  Change from baseline to week 14 0.19 0.10
  Change from baseline to week 104 0.05
Total back pain
 Baseline 0.06 −0.16 −0.16
  Change from baseline to week 14 0.15 −0.01
  Change from baseline to week 104 0.02
Morning stiffness
 Baseline −0.03 −0.07 −0.09
  Change from baseline to week 14 −0.14 0.02
  Change from baseline to week 104     0.06
*p<0.05.
†p<0.01.
‡p<0.001.
ASDAS, ankylosing spondylitis disease activity score; ASspiMRI-a, ankylosing spondylitis spinal magnetic resonance imaging activity; 
BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; CRP, C-reactive 
protein.
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that reader accuracy was affected by non-uniform image qual-
ity from the different study sites contributing MRI scans to this 
substudy. Also, the technical adequacy of the spinal segment 
(cervical, thoracic, lumbar) images, ie, 55.4% of spinal segment 
images were rated as having a ‘readable but not optimal’ image 
quality by one of the two readers, may limit the interpretation of 
our ﬁ  ndings. Scoring AS activity at the VU level could also have 
been impacted by reader discordance, eg, one reader might have 
scored a VU as containing an extensive diffuse lesion, while the 
other reader might have viewed the VU as having a high degree 
of background noise and not as inﬂ  amed. However, on a VU 
basis, only 1.3% of images had one reader score the unit while 
the other reader considered it unevaluable for scoring. Another 
possible study limitation relates to the ASspiMRI-a methodol-
ogy employed, which assesses the presence but not the degree 
of bone marrow oedema. As it has recently been shown that 
combined erosion plus bone marrow oedema ﬁ  ndings  yield 
enhanced MRI sensitivity in detecting AS,16 future studies may 
additionally include assessments of the degree of bone marrow 
oedema. However, whether this will increase the sensitivity to 
change remains to be demonstrated.
Improvement in ASspiMRI-a scores correlated with improve-
ment in the recently developed ASDAS, a discriminatory instru-
ment for assessing AS activity that includes patient-reported 
outcomes and CRP levels.13 Results of the correlation analyses 
also suggest that the greatest improvement in spinal inﬂ  amma-
tion measured by ASspiMRI-a is likely to occur in patients with 
higher AS disease activity at baseline, as assessed by ASspiMRI-a, 
before golimumab treatment. We observed weak or inconsistent 
correlations between MRI activity scores and disease activity 
assessed by BASDAI and no correlations between MRI activ-
ity scores and other clinical measures of physical function, back 
pain and morning stiffness. In contrast, signiﬁ  cant correlations 
were observed between ASspiMRI-a scores and CRP concentra-
tions. Although this link is not surprising because both CRP as 
an acute phase reactant and ASspiMRI-a score as an imaging 
marker of spinal inﬂ  ammation can be considered as objective 
indicators of AS inﬂ  ammation. Therefore, our data conﬁ  rm pre-
vious reports that changes in disease activity visible with MRI 
may not correlate with most clinical criteria such as pain, stiff-
ness, function, response to treatment (eg, ASAS20) and metrol-
ogy indices.3 6 7 However, this is the ﬁ  rst investigation to show 
that the MRI changes do correlate well with the new ASDAS 
and changes in CRP levels. While these ﬁ  ndings suggest that 
the ASDAS provides a more objective assessment of AS activity 
than other available clinical measures, we cannot exclude the 
possibility that the relationship is driven by CRP levels as they 
are a component of the ASDAS.
In summary, golimumab treatment signiﬁ  cantly reduced the 
MRI-detected spinal inﬂ  ammation in AS by week 14, and the 
improvements were maintained to week 104. Improvements 
in spinal inﬂ   ammation correlated with improvements in 
ASDAS and CRP levels, an objective measure of inﬂ  amma-
tion, but not with various other subjective measures of clinical 
improvement.
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